Percentageneeded to beconsidered HR+(adjuvantendocrine therapyconsidered)VenlafaxineOlaparib10yearsExemestane1yearAnthracyclinesTDM-1(Ado-trastuzumabemtansine)ChemoendocrinetherapyTamoxifenTaxanesPertuzumabTNBCCapecitabineAbemaciclibIntermediate(11-25)RadiationtherapyPembrolizumab2yearsLoperamideprophylaxisTC (docetaxel /cyclophosphamide)LVEFmonitoringEverymonthAromataseinhibitorsPercentageneeded to beconsidered HR+(adjuvantendocrine therapyconsidered)VenlafaxineOlaparib10yearsExemestane1yearAnthracyclinesTDM-1(Ado-trastuzumabemtansine)ChemoendocrinetherapyTamoxifenTaxanesPertuzumabTNBCCapecitabineAbemaciclibIntermediate(11-25)RadiationtherapyPembrolizumab2yearsLoperamideprophylaxisTC (docetaxel /cyclophosphamide)LVEFmonitoringEverymonthAromataseinhibitors

Early-Stage Breast Cancer - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. Percentage needed to be considered HR+ (adjuvant endocrine therapy considered)
  2. Venlafaxine
  3. Olaparib
  4. 10 years
  5. Exemestane
  6. 1 year
  7. Anthracyclines
  8. TDM-1 (Ado-trastuzumab emtansine)
  9. Chemoendocrine therapy
  10. Tamoxifen
  11. Taxanes
  12. Pertuzumab
  13. TNBC
  14. Capecitabine
  15. Abemaciclib
  16. Intermediate (11-25)
  17. Radiation therapy
  18. Pembrolizumab
  19. 2 years
  20. Loperamide prophylaxis
  21. TC (docetaxel / cyclophosphamide)
  22. LVEF monitoring
  23. Every month
  24. Aromatase inhibitors